Renowned oncologist questions Joe Biden's prostate cancer diagnosis timeline – and when treatments possibly started: ‘Doesn't make any sense'
A leading oncologist questioned the timeline of former President Biden's prostate cancer diagnosis, particularly the claim by his doctors that his form of the disease was 'hormone sensitive,' which they said allows for more effective treatment.
Speaking on SiriusXM's 'The Megyn Kelly Show,' urology and prostate physician, Dr. David B. Samadi questioned how Biden's doctors could know this unless the 82-year-old was already undergoing cancer treatment.
'A week ago, they had the prostate nodule. Within a week they did the biopsy and got the disease, so very quickly – based on the story they're telling – they've been able to do the staging part to find out if the cancer has spread to the bone or not,' he said.
Dr. David B. Samadi questioned how doctors could know that Biden's cancer was 'hormone sensitive' unless he was already undergoing cancer treatment.
Sirius
'But you have to give the injections and see if the patient responds. We don't know what his PSA is,' he said, referring to the score for the Prostate-Specific Antigen test — a critical diagnostic for prostate cancer patients.
Follow the latest on Joe Biden's prostate cancer diagnosis:
'If the PSA starts to go down, that's when you know he's hormone sensitive. I don't know how they'd be able to give all of this information from diagnosis to treatment to all of that within one week. The story doesn't make any sense.'
Another urologic oncologist told The Post that '98-99% if not more' of prostate cancers are sensitive to hormone therapy, 'because testosterone is the fuel by which prostate cancer grows.'
US President Joe Biden looks on after he delivered his farewell address to the nation from the Oval Office of the White House on January 15, 2025 in Washington, DC.
Getty Images
'For a patient who's newly diagnosed with prostate cancer, if we put them on one of the hormone-suppressing medications, we expect their PSA to decline,' said Manish Vira, Chief of Urology at Northwell Health Cancer Institute.
'We expect the cancer to shrink, because virtually all prostate cancers are sensitive to testosterone.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 reasons your Obamacare premiums are going up next year
If you happen to be one of the roughly 24 million people in America who buy their health insurance through the Affordable Care Act's marketplaces, you're probably in for some sticker shock next year. Many families could be on the hook for hundreds, and in some cases thousands, of dollars more in premium payments thanks to the expiration of Biden-era coverage subsidies. A little-talked-about change in the GOP's tax bill could also bump up costs by ending a practice among insurers known as 'silver loading,' which juiced the amount of financial help households could qualify for when buying a health plan. Meanwhile, higher premiums and new red tape contained in the GOP's bill are expected to push younger, healthier customers out of the market. As a result, carriers are already signaling their intention to raise their rates by more than usual next year to deal with the cost of a smaller and sicker customer base. Here's what you need to know about the potential triple whammy. The Biden administration temporarily upgraded the Affordable Care Act (ACA) by offering insurance shoppers much larger tax credits to help them buy coverage. Those changes dropped some premiums to zero and decreased out-of-pocket costs for lower-income families, and for the first time, capped monthly payments for households earning more than 400% of the poverty line, limiting costs to 8.5% of their income. The enhanced insurance subsidies are set to expire next year, which means premiums will spike. As the Urban Institute calculated last year, that could leave some lower-income households paying 80% more. People with incomes above 400% of the poverty line — $62,000 for an individual, or $128,000 for a family of four — will no longer receive any help. This year, that would have meant paying an extra $2,900, according to Urban's calculations. These changes are going to be particularly important for freelancers and small-business owners who tend to rely on the individual insurance market, as well as service industry workers who don't receive health coverage through their jobs. For most of this past decade, many marketplace customers have been able to get a free bronze plan or very cheap gold-level coverage courtesy of a quirk that developed after Trump tried to cut funding to Obamacare during his first term. Those days will likely soon be over, thanks to the new tax bill. The backstory is a bit technical: Under the ACA, lower-income households who buy coverage from the marketplace get big discounts that shrink their out-of-pocket expenses like copays and deductibles. The federal government was supposed to pay insurers directly to cover these so-called 'cost-sharing reductions.' But Trump cut off that flow of payments in 2017, seizing on what was essentially a legal hole in the Affordable Care Act after Republicans failed to repeal the statute. The president's move was expected to seriously weaken the markets. Instead, states and insurers found a workaround known as silver loading that made coverage cheaper for many Americans while adding to the federal government's expense. Rather than try to make up for the lost payments by upping the prices of all of their health plans, carriers only increased the cost of the silver plans that are used to calculate the value of the tax credits enrollees could receive. This allowed insurers to recoup their costs and increased the subsidies that households were eligible for, with the side effect that people could suddenly get free bronze or cheaper gold insurance. As part of their tax and spending bill, Republicans are planning to save some money by restoring the old cost-sharing reduction payments. In essence, they'll be restoring this aspect of the Affordable Care Act to how it was originally supposed to work, but it will also make the law's tax credits a bit less generous and kill the option of buying those super-cheap bronze or gold plans. By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy The coming cuts to Obamacare's subsidies are expected to lead many young and healthier enrollees to drop their coverage. The same goes for parts of the GOP bill that will likely make buying and maintaining ACA coverage more difficult, such as ending the ability to automatically re-enroll in your health plan from year to year. As a result, experts anticipate that insurers will have to increase the unsubsidized price of coverage by more than usual this coming year, since older, sicker patients cost more to insure. Already, there are signs of that happening. According to a review by the think tank KFF, insurers in Vermont, Oregon, Washington, and Washington, D.C., are requesting an additional 4% increase in their rates for next year, specifically because they expect the market to shrink when Biden's enhanced subsidies expire. Those price hikes won't affect households that get subsidized coverage, which caps their premium payments at a share of their income. But they will be felt by households that earn above 400% of the poverty mark, since they'll no longer receive tax credits. If you're middle-income and self-employed, be prepared for a big pop in your insurance bill. Jordan Weissmann is a senior reporter at Yahoo Finance. Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
3 reasons your Obamacare premiums are going up next year
If you happen to be one of the roughly 24 million people in America who buy their health insurance through the Affordable Care Act's marketplaces, you're probably in for some sticker shock next year. Many families could be on the hook for hundreds, and in some cases thousands, of dollars more in premium payments thanks to the expiration of Biden-era coverage subsidies. A little-talked-about change in the GOP's tax bill could also bump up costs by ending a practice among insurers known as 'silver loading,' which juiced the amount of financial help households could qualify for when buying a health plan. Meanwhile, higher premiums and new red tape contained in the GOP's bill are expected to push younger, healthier customers out of the market. As a result, carriers are already signaling their intention to raise their rates by more than usual next year to deal with the cost of a smaller and sicker customer base. Here's what you need to know about the potential triple whammy. The Biden administration temporarily upgraded the Affordable Care Act (ACA) by offering insurance shoppers much larger tax credits to help them buy coverage. Those changes dropped some premiums to zero and decreased out-of-pocket costs for lower-income families, and for the first time, capped monthly payments for households earning more than 400% of the poverty line, limiting costs to 8.5% of their income. The enhanced insurance subsidies are set to expire next year, which means premiums will spike. As the Urban Institute calculated last year, that could leave some lower-income households paying 80% more. People with incomes above 400% of the poverty line — $62,000 for an individual, or $128,000 for a family of four — will no longer receive any help. This year, that would have meant paying an extra $2,900, according to Urban's calculations. These changes are going to be particularly important for freelancers and small-business owners who tend to rely on the individual insurance market, as well as service industry workers who don't receive health coverage through their jobs. For most of this past decade, many marketplace customers have been able to get a free bronze plan or very cheap gold-level coverage courtesy of a quirk that developed after Trump tried to cut funding to Obamacare during his first term. Those days will likely soon be over, thanks to the new tax bill. The backstory is a bit technical: Under the ACA, lower-income households who buy coverage from the marketplace get big discounts that shrink their out-of-pocket expenses like copays and deductibles. The federal government was supposed to pay insurers directly to cover these so-called 'cost-sharing reductions.' But Trump cut off that flow of payments in 2017, seizing on what was essentially a legal hole in the Affordable Care Act after Republicans failed to repeal the statute. The president's move was expected to seriously weaken the markets. Instead, states and insurers found a workaround known as silver loading that made coverage cheaper for many Americans while adding to the federal government's expense. Rather than try to make up for the lost payments by upping the prices of all of their health plans, carriers only increased the cost of the silver plans that are used to calculate the value of the tax credits enrollees could receive. This allowed insurers to recoup their costs and increased the subsidies that households were eligible for, with the side effect that people could suddenly get free bronze or cheaper gold insurance. As part of their tax and spending bill, Republicans are planning to save some money by restoring the old cost-sharing reduction payments. In essence, they'll be restoring this aspect of the Affordable Care Act to how it was originally supposed to work, but it will also make the law's tax credits a bit less generous and kill the option of buying those super-cheap bronze or gold plans. By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy The coming cuts to Obamacare's subsidies are expected to lead many young and healthier enrollees to drop their coverage. The same goes for parts of the GOP bill that will likely make buying and maintaining ACA coverage more difficult, such as ending the ability to automatically re-enroll in your health plan from year to year. As a result, experts anticipate that insurers will have to increase the unsubsidized price of coverage by more than usual this coming year, since older, sicker patients cost more to insure. Already, there are signs of that happening. According to a review by the think tank KFF, insurers in Vermont, Oregon, Washington, and Washington, D.C., are requesting an additional 4% increase in their rates for next year, specifically because they expect the market to shrink when Biden's enhanced subsidies expire. Those price hikes won't affect households that get subsidized coverage, which caps their premium payments at a share of their income. But they will be felt by households that earn above 400% of the poverty mark, since they'll no longer receive tax credits. If you're middle-income and self-employed, be prepared for a big pop in your insurance bill. Jordan Weissmann is a senior reporter at Yahoo Finance. Sign up for the Mind Your Money newsletter Sign in to access your portfolio
New York Post
4 hours ago
- New York Post
Ozempic makes you twice as likely to develop this debilitating condition — what that really means for your risk
A growing number of Ozempic and Mounjaro users have shared stark warnings after going blind while using GLP-1 drugs. Now a new study is bringing into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease. But despite seemingly alarming numbers, a doctor explained to The Post why she doesn't actually think it should steer people away from the jab. 3 A 2024 study found that 12% of the US population has taken a GLP-1 drug at some point, with around 6% currently using them. alones – Published in JAMA Ophthalmology, the study was drawn from the health records of nearly 140,000 patients. Researchers found that after one year, GLP-1 users were more than twice as likely to develop neovascular age-related macular degeneration than those who were not taking the drugs. Age-related macular degeneration (AMD) is a disease that gradually damages the macula, the part of your eye's retina responsible for sharp, central vision. As it worsens, people find it increasingly difficult to see things directly in front of them, while their peripheral vision remains largely unaffected. In older people, AMD is a leading cause of irreversible blindness. The study found the risk percentage was 0.2% in GLP-1 users and 0.1% in nonusers. Nearly 20 million adults in the US are living with AMD, which comes in two types. The slower-moving dry AMD makes up about 80% of cases. It occurs when the macula gets thinner with age, often due to the buildup of yellow protein deposits known as drusen, according to the American Academy of Ophthalmology. Wet AMD, also known as neovascular AMD (nAMD), while less common, is far more aggressive, causing rapid and severe vision loss. In this form, the macula's function is compromised by the growth and leakage of abnormal blood vessels beneath the retina. The condition is typically treated with frequent injections to restore or stabilize vision. 3 Kaden notes that while there is cause for concern, headlines will amplify what she believes is a relatively low risk Northwell Foundation 'What researchers in this latest study were looking for specifically was whether or not these were people who converted from the dry form of macular degeneration, which is where you don't have abnormal blood vessels to the wet form, which is when you do,' Dr. Talia Kaden, director of the Northwell Health retina fellowship told the Post. But Kaden noted that while there is cause for concern, she actually believes there a relatively low risk. 'We're talking about a handful of patients who might have an increase in retinopathy compared to the millions of patients on these medications.' Dr. Talia Kaden 'That 2X number is really powerful, but when you look at the raw data, I don't think it's quite as strong a punch. I don't think that number should be a reason for people not to be on these drugs. I do think, though, it is worth continuing to look into,' she said. This study adds to a growing body of research documenting vision problems in patients using GLP-1 drugs. A review published earlier this year in JAMA Ophthalmology uncovered at least nine cases of patients who experienced vision loss after taking semaglutide or tirzepatide, the active ingredients in Wegovy and Zepbound, respectively. And a 2024 study suggested a potential link between semaglutide and the rare eye condition nonarteritic anterior ischemic optic neuropathy (NAION), in which restricted blood flow to the optic nerve causes sudden-onset vision loss. 'None of these studies are definitive in identifying that there has been a change. Some of them show a slight increase, but we're talking about a handful of patients who might have an increase in retinopathy compared to the millions of patients on these medications,' Kaden said. 3 In older people, AMD is a leading cause of irreversible blindness. StockPhotoPro – Researchers think that declining blood glucose levels caused by GLP-1s could trigger abnormal blood vessel growth in the retina. Further, there are GLP-1 receptors in the retina, and these drugs increase the levels of molecules that lead to harmful blood vessel formation. 'Seeing such a clear signal in our study was striking,' co-author Reut Shor of the University of Toronto told STAT. 'The absolute risk remains low, but the advanced form of AMD is a condition with serious implications for vision and quality of life. So a doubling of risk is clinically meaningful, particularly for vulnerable populations like older adults who may already be at elevated baseline risk.' Shor and his team note that more research is necessary to determine whether direct or indirect effects are causing the increased risk of nAMD. Shor and Kaden maintain that these findings should not be cause for alarm nor a reason to halt the prescription or use of these medications; rather, patients should be made aware of the risk and monitor their vision accordingly. Kaden, the study authors, and other experts recommend that GLP-1 users be on the lookout for any vision changes that could indicate early signs of AMD. 'We really want you to look for anything blurring, any new distortion. If you're looking at a flagpole or a doorframe, that should be a straight line. If all of a sudden that line looks wavy or curvy, that's a reason to seek a consultation with a retina specialist,' said Kaden.
